{"id":1012943,"date":"2026-10-22T18:42:54","date_gmt":"2026-10-22T22:42:54","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/agenus-to-provide-third-quarter-2026-financial-report-and-development-update\/"},"modified":"2026-10-22T18:42:54","modified_gmt":"2026-10-22T22:42:54","slug":"agenus-to-provide-third-quarter-2026-financial-report-and-development-update","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/agenus-to-provide-third-quarter-2026-financial-report-and-development-update\/","title":{"rendered":"Agenus to Provide Third Quarter 2026 Financial Report and Development Update"},"content":{"rendered":"<p>        <!--body {font:normal small Arial,Helvetica,sans-serif;color:#000;background-color:#fff;padding:24px;margin:0;} a img {border:0;} h3 {font-size:medium;color:#000;margin:0 0 1em 0; text-align:center;}-->  <\/p>\n<p><b>Agenus to Provide Third Quarter 2026 Financial Report and Development Update<\/b><\/p>\n<p>LEXINGTON, Mass.&#8211;(<a href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;<a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.agenusbio.com&amp;esheet=54627341&amp;newsitemid=20261022361178&amp;lan=en-US&amp;anchor=Agenus+Inc.&amp;index=1&amp;md5=cfb803959090a1655daa7a13e1f7ebdd\"><b>Agenus Inc.<\/b><\/a> (\u201cAgenus\u201d) (Nasdaq: <b>AGEN<\/b>), a leader in immuno-oncology innovation, today announced that the Company will release its third quarter 2026 financial results before the market opens on Thursday, November 5, 2026.<\/p>\n<p>\nThe earnings release will review Agenus\u2019 recent progress in advancing botensilimab and balstilimab (BOT+BAL) toward the Phase 3 neoadjuvant ROBBIN trial in earlier-stage colon cancer and strengthening the clinical and regulatory foundation for the combination, which now includes its first marketing authorizations in Armenia. It will also cover Agenus\u2019 continued commitment to expanding access to BOT+BAL for more patients globally.<\/p>\n<p><b>About Agenus<\/b><\/p>\n<p>\nAgenus is a leading immuno-oncology company targeting cancer with a comprehensive pipeline of immunological agents. The company was founded in 1994 with a mission to expand patient populations benefiting from cancer immunotherapy through combination approaches, using a broad repertoire of antibody therapeutics, adoptive cell therapies (through MiNK Therapeutics) and adjuvants. Agenus has robust end-to-end development capabilities, across commercial and clinical cGMP manufacturing facilities, research and discovery, and a global clinical operations footprint. Agenus is headquartered in Lexington, MA. For more information, visit <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.agenusbio.com&amp;esheet=54627341&amp;newsitemid=20261022361178&amp;lan=en-US&amp;anchor=www.agenusbio.com&amp;index=2&amp;md5=b2ac800bd26cf3909500434acfa3763b\">www.agenusbio.com<\/a> or @agenus_bio. Information that may be important to investors will be routinely posted on our website and social media channels.<\/p>\n<p><b>About Botensilimab (BOT)<\/b><\/p>\n<p>\nBotensilimab (BOT) is a human multifunctional, Fc-enhanced anti-CTLA-4 antibody designed to boost both innate and adaptive anti-tumor immune responses. Its novel design leverages mechanisms of action to extend immunotherapy benefits to \u201ccold\u201d tumors which generally respond poorly to standard of care or are refractory to conventional PD-1\/CTLA-4 therapies and investigational therapies. BOT augments immune responses across a wide range of tumor types by priming and activating T cells, reducing intratumoral regulatory T cells, activating myeloid cells and inducing durable memory responses.<\/p>\n<p>\nBOT+ balstilimab (BAL) has been studied in over 1,500 patients across more than nine tumor types, spanning late-line refractory disease and early-stage neoadjuvant settings. The combination is being developed to expand immunotherapy benefit to more patients, including those with microsatellite stable (MSS) disease and tumors considered immunologically \u201ccold\u201d or resistant to existing immunotherapies. Agenus\u2019 Phase 3 ROBBIN study is designed to evaluate BOT+BAL given before surgery in earlier-stage colon cancer.<\/p>\n<p>\nFor more information about botensilimab trials, visit <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.clinicaltrials.gov&amp;esheet=54627341&amp;newsitemid=20261022361178&amp;lan=en-US&amp;anchor=www.clinicaltrials.gov&amp;index=3&amp;md5=5a8b65f27bf226e3a518351d14591f73\">www.clinicaltrials.gov<\/a>.<\/p>\n<p><b>About Balstilimab (BAL)<\/b><\/p>\n<p>\nBalstilimab is a novel, fully human monoclonal immunoglobulin G4 (IgG4) designed to block PD-1 (programmed cell death protein 1) from interacting with its ligands PD-L1 and PD-L2. It has been evaluated in more than 900 patients to date and has demonstrated clinical activity and a favorable tolerability profile in several tumor types.<\/p>\n<p>\nThe Ministry of Health of the Republic of Armenia has granted marketing authorizations for Botvymo<sup>\u00ae<\/sup> (botensilimab) and Evamplix<sup>\u00ae<\/sup> (balstilimab), each approved for use in combination with the other for the treatment of adult patients with microsatellite stable (MSS) metastatic colorectal cancer (mCRC) without active liver metastases who have previously received available standard therapies. Botvymo and Evamplix were separately submitted and approved for use as a combination regimen. Their use in other indications and in other countries remains investigational.<\/p>\n<p><b>Forward-Looking Statements<\/b><\/p>\n<p>\nThis press release contains forward-looking statements that are made pursuant to the safe harbor provisions of the federal securities laws, including statements regarding its botensilimab and balstilimab programs, expected regulatory timelines and filings, and any other statements containing the words &#8220;may,&#8221; &#8220;believes,&#8221; &#8220;expects,&#8221; &#8220;anticipates,&#8221; &#8220;hopes,&#8221; &#8220;intends,&#8221; &#8220;plans,&#8221; &#8220;forecasts,&#8221; &#8220;estimates,&#8221; &#8220;will,&#8221; \u201cestablish,\u201d \u201cpotential,\u201d \u201csuperiority,\u201d \u201cbest in class,\u201d and similar expressions are intended to identify forward-looking statements. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially. These risks and uncertainties include, among others, the factors described under the Risk Factors section of our most recent Annual Report on Form 10-K for 2025, and subsequent Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commission. Agenus cautions investors not to place considerable reliance on the forward-looking statements contained in this release. These statements speak only as of the date of this press release, and Agenus undertakes no obligation to update or revise the statements, other than to the extent required by law. All forward-looking statements are expressly qualified in their entirety by this cautionary statement.<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20261022361178r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\" \/><span class=\"bwct31415\" \/><\/p>\n<p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">View source version on businesswire.com: <\/span><span id=\"mmgallerylink-link\"><a href=\"https:\/\/www.businesswire.com\/news\/home\/20261022361178\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20261022361178\/en\/<\/a><\/span><\/p>\n<p>\nInvestors: 917-362-1370 | <a rel=\"nofollow\" href=\"mailto:investor@agenusbio.com\">investor@agenusbio.com<br \/>\n<\/a><br \/>Media: 781-674-4422 | <a rel=\"nofollow\" href=\"mailto:communications@agenusbio.com\">communications@agenusbio.com<\/a><\/p>\n<p><b>KEYWORDS:<\/b> Massachusetts United States North America<\/p>\n<p><b>INDUSTRY KEYWORDS:<\/b> Biotechnology Health Pharmaceutical Clinical Trials Oncology<\/p>\n<p><b>MEDIA:<\/b><\/p>\n<table cellpadding=\"3\" cellspacing=\"3\">\n<tr>\n<td><font face=\"Arial\" size=\"2\"><b>Logo<\/b><\/font><\/td>\n<\/tr>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20261022361178\/en\/2688608\/3\/Color_Logo_Wh_Background-2026.jpg\" alt=\"Logo\" \/><\/td>\n<\/tr>\n<tr>\n<td><font face=\"Arial\" size=\"2\"><\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"<p>Agenus to Provide Third Quarter 2026 Financial Report and Development Update LEXINGTON, Mass.&#8211;(BUSINESS WIRE)&#8211;Agenus Inc. (\u201cAgenus\u201d) (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that the Company will release its third quarter 2026 financial results before the market opens on Thursday, November 5, 2026. The earnings release will review Agenus\u2019 recent progress in advancing botensilimab and balstilimab (BOT+BAL) toward the Phase 3 neoadjuvant ROBBIN trial in earlier-stage colon cancer and strengthening the clinical and regulatory foundation for the combination, which now includes its first marketing authorizations in Armenia. It will also cover Agenus\u2019 continued commitment to expanding access to BOT+BAL for more patients globally. About Agenus Agenus is a leading immuno-oncology company targeting cancer with a comprehensive pipeline of &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/agenus-to-provide-third-quarter-2026-financial-report-and-development-update\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Agenus to Provide Third Quarter 2026 Financial Report and Development Update&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-1012943","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.7 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Agenus to Provide Third Quarter 2026 Financial Report and Development Update - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/agenus-to-provide-third-quarter-2026-financial-report-and-development-update\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Agenus to Provide Third Quarter 2026 Financial Report and Development Update - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Agenus to Provide Third Quarter 2026 Financial Report and Development Update LEXINGTON, Mass.&#8211;(BUSINESS WIRE)&#8211;Agenus Inc. (\u201cAgenus\u201d) (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that the Company will release its third quarter 2026 financial results before the market opens on Thursday, November 5, 2026. The earnings release will review Agenus\u2019 recent progress in advancing botensilimab and balstilimab (BOT+BAL) toward the Phase 3 neoadjuvant ROBBIN trial in earlier-stage colon cancer and strengthening the clinical and regulatory foundation for the combination, which now includes its first marketing authorizations in Armenia. It will also cover Agenus\u2019 continued commitment to expanding access to BOT+BAL for more patients globally. About Agenus Agenus is a leading immuno-oncology company targeting cancer with a comprehensive pipeline of &hellip; Continue reading &quot;Agenus to Provide Third Quarter 2026 Financial Report and Development Update&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/agenus-to-provide-third-quarter-2026-financial-report-and-development-update\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-10-22T22:42:54+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20261022361178r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/agenus-to-provide-third-quarter-2026-financial-report-and-development-update\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/agenus-to-provide-third-quarter-2026-financial-report-and-development-update\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Agenus to Provide Third Quarter 2026 Financial Report and Development Update\",\"datePublished\":\"2026-10-22T22:42:54+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/agenus-to-provide-third-quarter-2026-financial-report-and-development-update\\\/\"},\"wordCount\":742,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/agenus-to-provide-third-quarter-2026-financial-report-and-development-update\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20261022361178r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/agenus-to-provide-third-quarter-2026-financial-report-and-development-update\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/agenus-to-provide-third-quarter-2026-financial-report-and-development-update\\\/\",\"name\":\"Agenus to Provide Third Quarter 2026 Financial Report and Development Update - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/agenus-to-provide-third-quarter-2026-financial-report-and-development-update\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/agenus-to-provide-third-quarter-2026-financial-report-and-development-update\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20261022361178r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"datePublished\":\"2026-10-22T22:42:54+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/agenus-to-provide-third-quarter-2026-financial-report-and-development-update\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/agenus-to-provide-third-quarter-2026-financial-report-and-development-update\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/agenus-to-provide-third-quarter-2026-financial-report-and-development-update\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20261022361178r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20261022361178r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/agenus-to-provide-third-quarter-2026-financial-report-and-development-update\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Agenus to Provide Third Quarter 2026 Financial Report and Development Update\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Agenus to Provide Third Quarter 2026 Financial Report and Development Update - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/agenus-to-provide-third-quarter-2026-financial-report-and-development-update\/","og_locale":"en_US","og_type":"article","og_title":"Agenus to Provide Third Quarter 2026 Financial Report and Development Update - Market Newsdesk","og_description":"Agenus to Provide Third Quarter 2026 Financial Report and Development Update LEXINGTON, Mass.&#8211;(BUSINESS WIRE)&#8211;Agenus Inc. (\u201cAgenus\u201d) (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that the Company will release its third quarter 2026 financial results before the market opens on Thursday, November 5, 2026. The earnings release will review Agenus\u2019 recent progress in advancing botensilimab and balstilimab (BOT+BAL) toward the Phase 3 neoadjuvant ROBBIN trial in earlier-stage colon cancer and strengthening the clinical and regulatory foundation for the combination, which now includes its first marketing authorizations in Armenia. It will also cover Agenus\u2019 continued commitment to expanding access to BOT+BAL for more patients globally. About Agenus Agenus is a leading immuno-oncology company targeting cancer with a comprehensive pipeline of &hellip; Continue reading \"Agenus to Provide Third Quarter 2026 Financial Report and Development Update\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/agenus-to-provide-third-quarter-2026-financial-report-and-development-update\/","og_site_name":"Market Newsdesk","article_published_time":"2026-10-22T22:42:54+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20261022361178r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/agenus-to-provide-third-quarter-2026-financial-report-and-development-update\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/agenus-to-provide-third-quarter-2026-financial-report-and-development-update\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Agenus to Provide Third Quarter 2026 Financial Report and Development Update","datePublished":"2026-10-22T22:42:54+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/agenus-to-provide-third-quarter-2026-financial-report-and-development-update\/"},"wordCount":742,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/agenus-to-provide-third-quarter-2026-financial-report-and-development-update\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20261022361178r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/agenus-to-provide-third-quarter-2026-financial-report-and-development-update\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/agenus-to-provide-third-quarter-2026-financial-report-and-development-update\/","name":"Agenus to Provide Third Quarter 2026 Financial Report and Development Update - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/agenus-to-provide-third-quarter-2026-financial-report-and-development-update\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/agenus-to-provide-third-quarter-2026-financial-report-and-development-update\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20261022361178r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","datePublished":"2026-10-22T22:42:54+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/agenus-to-provide-third-quarter-2026-financial-report-and-development-update\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/agenus-to-provide-third-quarter-2026-financial-report-and-development-update\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/agenus-to-provide-third-quarter-2026-financial-report-and-development-update\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20261022361178r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20261022361178r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/agenus-to-provide-third-quarter-2026-financial-report-and-development-update\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Agenus to Provide Third Quarter 2026 Financial Report and Development Update"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1012943","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=1012943"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1012943\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=1012943"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=1012943"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=1012943"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}